LENZ Therapeutics, Inc. (NASDAQ:LENZ) Shares Sold by Alliancebernstein L.P.

Alliancebernstein L.P. lessened its holdings in shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ) by 18.8% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 7,586 shares of the company’s stock after selling 1,760 shares during the period. Alliancebernstein L.P.’s holdings in LENZ Therapeutics were worth $219,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. State Street Corp lifted its position in shares of LENZ Therapeutics by 18.7% during the 3rd quarter. State Street Corp now owns 289,154 shares of the company’s stock worth $6,865,000 after buying an additional 45,600 shares during the last quarter. Jane Street Group LLC acquired a new position in LENZ Therapeutics in the third quarter valued at $286,000. Barclays PLC grew its holdings in shares of LENZ Therapeutics by 273.1% during the third quarter. Barclays PLC now owns 16,463 shares of the company’s stock worth $391,000 after purchasing an additional 12,051 shares during the last quarter. Harbor Capital Advisors Inc. acquired a new stake in shares of LENZ Therapeutics during the fourth quarter worth about $1,270,000. Finally, SG Americas Securities LLC boosted its position in shares of LENZ Therapeutics by 20.7% in the 4th quarter. SG Americas Securities LLC now owns 5,458 shares of the company’s stock valued at $158,000 after purchasing an additional 935 shares during the period. Hedge funds and other institutional investors own 54.32% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the company. HC Wainwright reiterated a “buy” rating and issued a $38.00 price objective on shares of LENZ Therapeutics in a research note on Wednesday, April 16th. Citigroup increased their price target on shares of LENZ Therapeutics from $44.00 to $47.00 and gave the stock a “buy” rating in a research note on Thursday, March 20th. Piper Sandler began coverage on shares of LENZ Therapeutics in a research note on Monday, April 14th. They issued an “overweight” rating and a $51.00 price objective on the stock. Finally, TD Cowen began coverage on LENZ Therapeutics in a report on Tuesday, March 18th. They set a “buy” rating and a $60.00 price target on the stock. Five equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, LENZ Therapeutics presently has an average rating of “Buy” and an average price target of $46.60.

LENZ Therapeutics Price Performance

Shares of LENZ stock opened at $24.11 on Tuesday. LENZ Therapeutics, Inc. has a 1-year low of $14.42 and a 1-year high of $38.93. The business’s fifty day moving average price is $23.45 and its 200 day moving average price is $27.13. The firm has a market capitalization of $664.06 million, a PE ratio of -5.05 and a beta of 0.43.

LENZ Therapeutics (NASDAQ:LENZ) last released its quarterly earnings data on Wednesday, March 19th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.42) by ($0.04). Equities research analysts expect that LENZ Therapeutics, Inc. will post -2.18 earnings per share for the current fiscal year.

LENZ Therapeutics Company Profile

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.